Papillary Type 1 vs Type 2: Key Differences & Comparisons
Papillary types 1 and 2 are distinct variants of papillary thyroid cancer, the most common type of thyroid cancer. Understanding their differences is crucial for accurate diagnosis and treatment. This article will delve into the key distinctions between these two types, their prognosis, and management strategies.
Thyroid cancer is grouped into several histological types, with papillary carcinoma being by far the most prevalent. Within this group, papillary carcinoma is further subclassified into various subtypes, the most significant being types 1 and 2. Let's explore the intricacies of each.
Papillary Type 1
Papillary type 1, also known as conventional papillary thyroid carcinoma (PTC), is the most common subtype, accounting for about 80% of all PTC cases. It is characterized by papillae, which are finger-like projections into cystic spaces, and by distinctive nuclear features under the microscope.
Type 1 PTC is further graded based on the extent of nuclear pleomorphism, increased mitoses, and the presence of necrosis, giving rise to two variants - classic and follicular-variant papillary thyroid carcinoma. The classic variant is more common and typically exhibits abundant intracellular mucin.
Nuclear Features of Papillary Type 1
Nuclear features are the hallmarks of papillary type 1. They includeSource: World Health Organization Classification of Tumors Editorial Board (2017). Thyroidfine chromatin, nuclear overlapping, and clearing, and nucleomegaly. These features are driven by specific gene mutations, most notably, the BRAF V600E mutation.
Examples of these nuclear alterations are evident in thyroidectomy specimens examined under a microscope. The clear realization of these features necessitates a closer examination of nuclear DNA for a conclusive diagnosis.
Incidence and Prognosis
The incidence of papillary type 1 is higher among women and increases with age. Despite its aggressive manifestations, it has a favorable prognosis. Overall, papillary type 1 has a 10-year survival rate higher than 90%. However, the prognosis is largely dependent on the tumor size and extent of spread at the time of diagnosis.
Complete surgical excision remains the mainstay of treatment for papillary type 1. Adjuvant radioactive iodine therapy and/or thyroid hormone therapy may be employed in selected cases to minimize recurrence.
Papillary Type 2
Once thought to be a morphological variant of type 1, papillary type 2 was formally recognized as a distinct entity in the 2017 WHO Classification. Unlike type 1, it is characterized by a solid, encapsulated growth pattern with minimal intrathryoid extension. This gives type 2 a more indolent course with an excellent prognosis.
Type 2 PTC is notably less common than type 1, comprising only about 3-5% of all PTC cases. Despite its rarity, it is more prevalent among children and young adults, and it tends to be larger in size at diagnosis.
Genetic Repertoire of Papillary Type 2
The genetic profile of papillary type 2 is distinct from that of type 1. Instead of the BRAF V600E mutation, type 2 is characterized by an ETS translocation, with ETV6-NTRK3 fusion being the most common. These translocations are thought to drive the aggressive growth pattern in papillary type 2.
The ETV6-NTRK3 fusion can be identified using molecular diagnostic techniques, which has diagnostic implications. It can also serve as a therapeutic target with specific drugs like Larotrectinib and Entrectinib.
Treatment and Prognosis of Papillary Type 2
The management strategy for papillary type 2 centers around surgery, tailored to the extent of the tumor. Besides, given its indolent nature and excellent prognosis, active surveillance can be an option when definitive treatment might carry significant risks.
Regardless of the type, close follow-up is crucial after treatment, with repeated thyroid function tests and neck sonograms. These help monitor for any recurrence, which although rare, can occur.
A keen understanding of papillary types 1 and 2 is fundamental for clinicians and pathologists. Their distinct genetic profiles deciphered through molecular testing has translated to targeted therapies in clinical practice, rallying progress in thyroid cancer management.